Key result
Beta-blockers and non-dihydropyridine calcium channel blockers represent the cornerstone of first-line medical therapy for symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy.
This review outlines the standard medical management of hypertrophic cardiomyopathy, highlighting beta-blockers as the primary treatment.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gregor et al. (2015) conducted a review in Hypertrophic cardiomyopathy. Pharmacotherapy (beta-blockers, calcium channel blockers) was evaluated. Beta-blockers and non-dihydropyridine calcium channel blockers represent the cornerstone of first-line medical therapy for symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: